Global $4.1 Billion Clinical Trial Supplies Market Report 2024-2034 - Emerging Markets Catalyzing Growth in Clinical Trial Supplies [Yahoo! Finance]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
World revenue for the Clinical Trial Supplies Market is forecast to surpass US$ 4.10 billion in 2024, with strong revenue growth through to 2034. Opportunities in Emerging Markets Projected to Boost Industry Growth Clinical trials are increasingly moving to developing economies like China India , and Japan in the Asia Pacific region, with significant growth in patient recruitment in countries such as China South Korea , and India due to lower costs compared to developed nations. Early phase clinical trials in developing nations are notably cheaper, making them an attractive option for pharmaceutical companies. For instance, in November 2023 , AstraZeneca forged a partnership with a Chinese biotechnology company to secure a position in the competitive KRAS G12D field, exchanging $24 million upfront. The agreement grants AstraZeneca a worldwide license to UA022, a small molecule inhibitor targeting the historically challenging oncogene, which was undergoing preclinical development
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralowBusiness Wire
- Ryanair's Michael O'Leary, who is up for a $108 million bonus, doesn't see high CEO pay as a problem: ‘Footballers are getting half a million a week' [Fortune]Fortune
- FTSE 100 continues record run boosted by Anglo American, AstraZeneca [Reuters]Reuters
- ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial [Yahoo!Yahoo!
- AstraZeneca: A Triple Shot Of Income, Growth, And Value [Seeking Alpha]Seeking Alpha
AZN
Sec Filings
- 4/29/24 - Form 6-K
- 4/29/24 - Form 6-K
- 4/25/24 - Form 6-K
- AZN's page on the SEC website